Patents Assigned to Ironwood Pharmaceuticals, Inc.
-
Publication number: 20120172325Abstract: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis employing. The methods and compositions employ guanosine 3?,5?-cyclic monophosphate pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 1, 2011Publication date: July 5, 2012Applicant: Ironwood Pharmaceuticals, Inc.Inventor: Mark G. Currie
-
Publication number: 20120149743Abstract: Derivatives of selenophene and selenazole heterocycles are disclosed. The compounds are useful as inhibitors of D-amino acid oxidase (DAO) and in the treatment of neurodegenerative and psychiatric diseases and disorders.Type: ApplicationFiled: June 2, 2009Publication date: June 14, 2012Applicant: Ironwood Pharmaceuticals, IncInventor: Regina Graul
-
Publication number: 20120108525Abstract: Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.Type: ApplicationFiled: November 8, 2011Publication date: May 3, 2012Applicant: IRONWOOD PHARMACEUTICALS, INC.Inventors: MARK G. CURRIE, SHALINA MAHAJAN-MIKLOS, LI JING SUN
-
Publication number: 20120088902Abstract: Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders and disorders and conditions associated with excess fluid and/or salt retention as well as other conditions and disorders are described. The compositions feature polypeptides that activate the guanylate cyclase C (GC-C) receptor.Type: ApplicationFiled: June 27, 2007Publication date: April 12, 2012Applicant: IRONWOOD PHARMACEUTICALS, INC.Inventors: Mark G. Currie, Daniel P. Zimmer
-
Publication number: 20120039949Abstract: Solid, stable formulations of GC-C receptor agonist polypeptide suitable for oral administration are described herein as are methods for preparing such formulations. The GC-C receptor agonist polypeptide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.Type: ApplicationFiled: August 14, 2009Publication date: February 16, 2012Applicant: Ironwood Pharmaceuticals, Inc.Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao
-
Patent number: 8110553Abstract: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.Type: GrantFiled: May 27, 2010Date of Patent: February 7, 2012Assignee: Ironwood Pharmaceuticals, Inc.Inventors: Mark G. Currie, Shalina Mahajan-Miklos, G. Todd Milne, Thea Norman
-
Patent number: 8101579Abstract: Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.Type: GrantFiled: September 28, 2009Date of Patent: January 24, 2012Assignee: Ironwood Pharmaceuticals, Inc.Inventors: Mark G. Currie, Shalina Mahajan-Miklos, Li Jing Sun
-
Publication number: 20120009225Abstract: Solid, stable formulations of therapeutic polypeptide suitable for oral administration are described herein as are methods for preparing such formulations. The therapeutic polypeptide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.Type: ApplicationFiled: August 14, 2009Publication date: January 12, 2012Applicant: Ironwood Pharmaceuticals, Inc.Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao
-
Patent number: 8088935Abstract: Compounds and methods for the treatment of asthma are disclosed. The methods involve mast cell stabilization together with selective inhibition of iNOS. The compounds are combinations of a mast cell inhibiting moiety and an inhibitor of iNOS.Type: GrantFiled: December 23, 2004Date of Patent: January 3, 2012Assignee: Ironwood Pharmaceuticals, Inc.Inventors: James Pearson, John J. Talley, Mark G. Currie
-
Publication number: 20110311483Abstract: Compounds of Formulae I-1 to I-9 are disclosed, which are modulators of CRTH2, particularly antagonists of CRTH2, that are useful for treating various disorders, including asthma and respiratory disorders.Type: ApplicationFiled: March 29, 2011Publication date: December 22, 2011Applicant: IRONWOOD PHARMACEUTICALS, INC.Inventors: James JIA, Regina GRAUL, Bo PENG, Colleen HUDSON, Joel MOORE, Ara MERMERIAN
-
Publication number: 20110312938Abstract: Disclosed are compounds and pharmaceutically acceptable salts of Formula (I) wherein R1, R2, R3, and RN are as defined herein. Compounds of Formula (I) are useful in the prevention and/or treatment of neurological and psychiatric disorder, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the disclosure and methods of treating the aforementioned conditions using such compounds.Type: ApplicationFiled: June 30, 2009Publication date: December 22, 2011Applicant: Ironwood Pharmaceuticals, Inc.Inventors: Regina Graul, John Jeffrey Talley, Ara Mermerian
-
Patent number: 8080526Abstract: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.Type: GrantFiled: April 5, 2010Date of Patent: December 20, 2011Assignee: Ironwood Pharmaceuticals, Inc.Inventors: Mark Currie, Shalina Mahajan-Miklos, G. Todd Milne, Thea Norman
-
Publication number: 20110306125Abstract: The present invention relates to compositions and methods for obtaining (e.g., expressing, isolating and/or purifying) polypeptides capable of binding to and/or activating the guanylate cyclase C receptor.Type: ApplicationFiled: June 30, 2009Publication date: December 15, 2011Applicant: Ironwood Pharmaceuticals, Inc.Inventor: Marco Kessler
-
Publication number: 20110275683Abstract: Derivatives of selenophene and selenazole heterocycles are disclosed. The compounds are useful as inhibitors of D-amino acid oxidase (DAO) and in the treatment of neurodegenerative and psychiatric diseases and disorders.Type: ApplicationFiled: June 2, 2009Publication date: November 10, 2011Applicant: Ironwood Pharmaceuticals, IncInventor: Regina Graul
-
Publication number: 20110160225Abstract: Disclosed herein are novel compositions and methods for treating or preventing a variety of disorders and conditions associated with lipid metabolism. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more fibric acid or statin derivative compositions alone or in combination with one or more lipid altering agents and/or PDE inhibitors.Type: ApplicationFiled: November 19, 2010Publication date: June 30, 2011Applicant: IRONWOOD PHARMACEUTICALS, INC.Inventors: Mark G. Currie, John Jeffrey Talley, Brian Cali
-
Patent number: 7960544Abstract: Indoles that have activity as inhibitors of FAAH are described as are indoles and indole derivatives that have activity as inhibitors of DAO.Type: GrantFiled: December 18, 2006Date of Patent: June 14, 2011Assignee: Ironwood Pharmaceuticals, Inc.Inventors: Wilmin Bartolini, Brian M. Cali, Barbara Chen, Yueh-Tyng Chien, Mark G. Currie, G. Todd Milne, James Philip Pearson, John Jeffrey Talley, Jane Yang, Craig Zimmerman, Charles Kim, Kevin Sprott, Timothy Barden, Regina Lundigran, Ara Mermerian
-
Publication number: 20110129433Abstract: Disclosed herein are novel compositions and methods for treating or preventing GI tract disorders and/or GERD-related respiratory disorders as well as protecting stratified squamous epithelium against injury by a noxious substance. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant, alone or in combination with at least one proton pump inhibitor, and optionally one or more agent chosen from antacids, histamine H2-receptor antagonists, ?-aminobutyricacid-b (GABA-B) agonists, prodrugs of GABA-B agonists, and protease inhibitors.Type: ApplicationFiled: June 26, 2009Publication date: June 2, 2011Applicant: IRONWOOD PHARMACEUTICALS, INC.Inventor: Mark G. Currie
-
Publication number: 20110124583Abstract: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.Type: ApplicationFiled: April 5, 2010Publication date: May 26, 2011Applicant: Ironwood Pharmaceuticals, Inc.Inventors: Mark G. Currie, Shalina Mahajan-Miklos, Thea Norman, G. Todd Milne
-
Publication number: 20110118195Abstract: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.Type: ApplicationFiled: May 27, 2010Publication date: May 19, 2011Applicant: Ironwood Pharmaceuticals, Inc.Inventors: Mark G. Currie, Shalina Mahajan-Miklos
-
Publication number: 20110118184Abstract: The present invention provides peptides that are useful for the treatment of gastrointestinal disorders. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms.Type: ApplicationFiled: November 9, 2010Publication date: May 19, 2011Applicant: Ironwood Pharmaceuticals, Inc.Inventors: Mark G. Currie, Angelika Fretzen, Marco Kessler, Daniel P. Zimmer